Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
RSA Biomedical AB
AB
Active
Org 5564933728
Tvistevägen 48, 907 36
Umeå
Manufacture of medical and dental instruments and supplies
·
NACE 3250
Est. 1994 · 31 years old
2 employees
Monitor
Share
Sweden
/
Companies
/
Manufacture of medical and dental instruments and supplies
/
RSA Biomedical AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
7M
6M
4M
2M
0M
2021: 6M
6M
2021
2022: 5M (-17% vs 2021)
5M
-17%
2022
2023: 5M (0% vs 2022)
5M
0%
2023
2024: 4M (-20% vs 2023)
4M
-20%
2024
2025: 4M (0% vs 2024)
4M
0%
2025
EBITDA
SEK millions
4M
3M
2M
1M
0M
2021: 3M
3M
2021
2022: 2M (-33% vs 2021)
2M
-33%
2022
2023: 2M (0% vs 2022)
2M
0%
2023
2024: 2M (0% vs 2023)
2M
0%
2024
2025: 1M (-50% vs 2024)
1M
-50%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
3 931
4 260
4 629
4 863
5 716
Staff expenses
−1 427
−1 455
−1 547
−1 896
—
EBITDA
1 423
1 963
2 230
2 043
2 563
Depreciation & amort.
−56
−75
−75
−75
−75
EBIT
1 367
1 888
2 155
1 968
2 488
Net financials
50
121
606
4
−3
Profit before tax
1 080
1 583
2 312
1 472
1 953
Tax
−238
−339
−382
−315
−408
Net profit
843
1 244
1 930
1 157
1 545
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
4 838
5 057
5 035
4 019
4 157
Equity
1 000
1 407
2 063
1 313
1 701
Long-term debt
—
—
—
—
0
Short-term debt
1 457
1 606
1 353
1 536
1 786
Total debt
1 457
1 606
1 353
1 536
1 786
Financial ratios
5-year trend
EBITDA margin
36,2 %
This company
15,8 %
Market median
This company
Market median
129% above market
2021
2025
Equity ratio
20,7 %
This company
38,2 %
Market median
This company
Market median
46% below market
2021
2025
Return on equity
84,3 %
This company
18,4 %
Market median
This company
Market median
358% above market
2021
2025
Net profit margin
21,4 %
This company
8,1 %
Market median
This company
Market median
164% above market
2021
2025
Asset turnover
0,81×
This company
1,12×
Market median
This company
Market median
28% below market
2021
2025
Debt / equity
3,84×
This company
0,62×
Market median
This company
Market median
519% above market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on RSA Biomedical AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
